Trial · NCT03573882
Results by group33
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 33
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Sickle Cell Disease (SCD)-Related Treatment Emergent Adverse Events (TEAEs) | Prior Treatment of Placebo in GBT440-031 (NCT03036813) | 47 | Participants | ||
| Number of Participants With Sickle Cell Disease (SCD)-Related Treatment Emergent Adverse Events (TEAEs) | Prior Treatment of Voxelotor 900mg in GBT440-031(NCT03036813) | 42 | Participants | ||
| Number of Participants With Sickle Cell Disease (SCD)-Related Treatment Emergent Adverse Events (TEAEs) | Prior Treatment of Voxelotor 1500 mg in GBT440-031(NCT03036813) | 42 | Participants | ||
| Number of Participants With Non- SCD-Related TEAEs | Prior Treatment of Placebo in GBT440-031 (NCT03036813) | 59 | Participants | ||
| Number of Participants With Non- SCD-Related TEAEs | Prior Treatment of Voxelotor 900mg in GBT440-031(NCT03036813) | 49 | Participants | ||
| Number of Participants With Non- SCD-Related TEAEs | Prior Treatment of Voxelotor 1500 mg in GBT440-031(NCT03036813) | 52 | Participants | ||
| Number of Participants With SCD-Related Treatment Emergent Serious Adverse Events (TESAEs) | Prior Treatment of Placebo in GBT440-031 (NCT03036813) | 39 | Participants | ||
| Number of Participants With SCD-Related Treatment Emergent Serious Adverse Events (TESAEs) | Prior Treatment of Voxelotor 900mg in GBT440-031(NCT03036813) | 33 | Participants | ||
| Number of Participants With SCD-Related Treatment Emergent Serious Adverse Events (TESAEs) | Prior Treatment of Voxelotor 1500 mg in GBT440-031(NCT03036813) | 22 | Participants | ||
| Number of Participants With Non-SCD-Related TESAEs | Prior Treatment of Placebo in GBT440-031 (NCT03036813) | 18 | Participants | ||
| Number of Participants With Non-SCD-Related TESAEs | Prior Treatment of Voxelotor 900mg in GBT440-031(NCT03036813) | 14 | Participants | ||
| Number of Participants With Non-SCD-Related TESAEs | Prior Treatment of Voxelotor 1500 mg in GBT440-031(NCT03036813) | 15 | Participants | ||
| Annualized Incidence Rate (Events Per Person Years) of SCD-Related Complications | Prior Treatment of Placebo in GBT440-031 (NCT03036813) | 1.181 | 95% Confidence Interval 1.031 to 1.347 | Events per person years | |
| Annualized Incidence Rate (Events Per Person Years) of SCD-Related Complications | Prior Treatment of Voxelotor 900mg in GBT440-031(NCT03036813) | 1.084 | 95% Confidence Interval 0.924 to 1.264 | Events per person years | |
| Annualized Incidence Rate (Events Per Person Years) of SCD-Related Complications | Prior Treatment of Voxelotor 1500 mg in GBT440-031(NCT03036813) | 1.045 | 95% Confidence Interval 0.905 to 1.200 | Events per person years | |
| Annualized Incidence Rate (VOC Events Per Person Years) of On-Treatment Vaso-occlusive Crisis (VOCs) | Prior Treatment of Placebo in GBT440-031 (NCT03036813) | 1.038 | 95% Confidence Interval 0.896 to 1.195 | VOC events per person years | |
| Annualized Incidence Rate (VOC Events Per Person Years) of On-Treatment Vaso-occlusive Crisis (VOCs) | Prior Treatment of Voxelotor 900mg in GBT440-031(NCT03036813) | 0.926 | 95% Confidence Interval 0.778 to 1.095 | VOC events per person years | |
| Annualized Incidence Rate (VOC Events Per Person Years) of On-Treatment Vaso-occlusive Crisis (VOCs) | Prior Treatment of Voxelotor 1500 mg in GBT440-031(NCT03036813) | 0.889 | 95% Confidence Interval 0.760 to 1.034 | VOC events per person years | |
| Change From Baseline in Hemoglobin Level at Week 48 | Prior Treatment of Placebo in GBT440-031 (NCT03036813) | Baseline | 8.8 | Standard Deviation 1.32 | Gram per deciliter (g/dL) |
| Change From Baseline in Hemoglobin Level at Week 48 | Prior Treatment of Voxelotor 900mg in GBT440-031(NCT03036813) | Baseline | 9.0 | Standard Deviation 1.52 | Gram per deciliter (g/dL) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03573882/results